Stem Cell Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cell Transplantation
Report summarizes cell transplantation study findings from University of Freiburg
August 25th, 2008
"Toxicity-reduced conditioning is being used for allogeneic stem cell transplantation in older and/or comorbid patients. We report on the treatment of 133 patients (median age: 55.6 years [23-73 years]) with acute myelold leukemia (AML)/myelodysplastic syndrome (MDS; In = 81), myeloprol iterative syndromes (MPS; n = 20), and lymphoid malignancies (n = 32) using conditioning with FBIVI: fludarabine (5 x 30 mg/m(2)), 1,3-bis(2-chloroethyl)-lnitrosourea (or carmustine, BCNU; 2 x 200 Mg/M2), and melphalan (140 mg/m(2))," investigators in Freiburg, Germany report. "Patients 55 years or older received fludarabine with reduced BCNU (2 x 150 mg/m(2)) and melphalan (110...
Source: Stem Cell Week (2008-08-25)
|
